FDA warning letter targets doctor who worked on a Takeda Phase 3 study
Back in January, Takeda won approval for a new indication for its primary immunodeficiency drug HyQvia, this time as a treatment for a rare autoimmune …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
